KRAS and non-small cell lung carcinoma: Subsequently, a series of small‐molecule TKIs targeting specific oncogenic drivers, including ALK, ROS1, KRAS, BRAF, MET, and NTRK, were developed and approved as the preferred treatments for advanced NSCLC.6